Real-World Data Reveal Limited Efficacy of Second-Line Therapies Following First-Line Enfortumab Vedotin + Pembrolizumab in aUC

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.26.300350
Cited by: 0

Abstract

Two retrospective analyses of data from the Flatiron Health Research Database (Abstract 676) and the UNITE Study (Abstract 705) evaluated real-world outcomes among patients with advanced urothelial carcinoma who received first-line enfortumab vedotin plus pembrolizumab followed by second-line therapy, offering early insights into practice patterns and clinical results in the post-progression setting.

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Prostate Cancer Treatment and Research

Publication details

Journal / source
Default Digital Object Group
Publication date
23 February 2026
Language
EN
Document type
Dataset